Investigators also glimpse to assess linvoseltamab in relapsed/refractory many myeloma as Section of the phase 3 LINKER-MM3 trial. Experimental: Dose expansion_sub-inhabitants 2_higher dose of niraparib MTDs and/or prospect RP2Ds for elimusertib utilized in combination with niraparib at a better fixed dose. Alterations which aren't annotated in OncoKB will should be https://peterf443rcm5.anchor-blog.com/profile